Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

This study has been withdrawn prior to enrollment.
(Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are rare (~3 in 1 million). No eligible subjects have been identified.)
Information provided by (Responsible Party):
Massachusetts Eye and Ear Infirmary Identifier:
First received: November 19, 2010
Last updated: November 3, 2015
Last verified: January 2015
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: January 2015
  Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)